MPI8  (Synonyms: TG0205221)

MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). This dual inhibition enhanced the overall antiviral potency and effect of MPI8. MPI8 can be used in clinical studies of COVID-19^[1][2].

600.75

C₃₂H₄₈N₄O₇

856242-63-2

O=C(N[C@H](C(N[C@H](C(N[C@H](C=O)C[C@H]1C(NCC1)=O)=O)CC2CCCCC2)=O)[C@@H](C)OC(C)(C)C)OCC3=CC=CC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ma X R, et al. MPI8 is potent against SARS‐CoV‐2 by inhibiting dually and selectively the SARS‐CoV‐2 main protease and the host cathepsin L[J]. ChemMedChem, 2022, 17(1): e202100456.  [Content Brief]

  [2]. Yang S, et al. Synthesis, crystal structure, structure− activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor[J]. Journal of medicinal chemistry, 2006, 49(16): 4971-4980.  [Content Brief]